Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 13/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488197 | 0.86 | EDNRA (0.48) | EDNRAKDM4ETSHRHSD17B10 | |
| SCHEMBL18488198 | 0.86 | EDNRA (0.48) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL689951 | 0.82 | KDM4E (0.43) | EDNRAKDM4EHSD17B10HTR6 | |
| SCHEMBL18487536 | 0.78 | KDM4E (0.48) | EDNRAKDM4ETSHRHSD17B10HTR6 | |
| SCHEMBL18487738 | 0.76 | DYRK1A (0.39) | EDNRAKDM4EHSD17B10HTR6 | |
| SCHEMBL18488204 | 0.76 | EDNRA (0.48) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL18487742 | 0.73 | DYRK1A (0.41) | EDNRAKDM4EHSD17B10HTR6 | |
| SCHEMBL689528 | 0.73 | DYRK1A (0.42) | EDNRAKDM4EHSD17B10HTR6 | |
| SCHEMBL18488201 | 0.73 | EDNRA (0.46) | EDNRAKDM4ENSD2TSHRHSD17B10 | |
| SCHEMBL18488196 | 0.72 | EDNRA (0.47) | EDNRAKDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017023916-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885NSD2 1055/4885 |
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885NSD2 1055/4885 |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885NSD2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.